Clinical variability and molecular heterogeneity in prostate cancer
Prostate cancer is a clinically heterogeneous disease, with some men having indolent disease that can safely be observed, while others have aggressive, lethal disease. Over the past decade, researchers have begun to unravel some of the genomic heterogeneity that contributes to these varying clinical...
Main Authors: | Jonathan Shoag, Christopher E Barbieri |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2016-01-01
|
Series: | Asian Journal of Andrology |
Subjects: | |
Online Access: | http://www.ajandrology.com/article.asp?issn=1008-682X;year=2016;volume=18;issue=4;spage=543;epage=548;aulast=Shoag |
Similar Items
-
SPOP mutation leads to genomic instability in prostate cancer
by: Gunther Boysen, et al.
Published: (2015-09-01) -
Molecular Cloning and Functional Studies of Two Kazal-Type Serine Protease Inhibitors Specifically Expressed by Nasonia vitripennis Venom Apparatus
by: Cen Qian, et al.
Published: (2015-08-01) -
SPINK1 is a Potential Diagnostic and Prognostic Biomarker for Sepsis
by: Chen D, et al.
Published: (2024-03-01) -
SPOP Deregulation Improves the Radiation Response of Prostate Cancer Models by Impairing DNA Damage Repair
by: Rihan El Bezawy, et al.
Published: (2020-06-01) -
Serine Protease Inhibitor Kazal Type 1, A Potential Biomarker for the Early Detection, Targeting, and Prediction of Response to Immune Checkpoint Blockade Therapies in Hepatocellular Carcinoma
by: Jianlong Jia, et al.
Published: (2022-07-01)